Type 17 CD8+ T cells display enhanced antitumor immunity.


Journal Article

Interleukin-17 (IL-17)-secreting CD8(+) T cells have been described, but they have not been thoroughly studied and they do not have a known role in cancer immunotherapy. We skewed CD8(+) T cells to secrete IL-17 through priming in Th17-polarizing conditions. IL-17-producing CD8(+) T cells demonstrated reduced expression of Eomes and diminished cytolytic differentiation in vitro. However, after adoptive transfer, these cells converted to interferon-gamma-producing effector cells and mediated regression of large, established tumors. This improved antitumor immunity was associated with increased expression of IL-7R-alpha, decreased expression of killer cell lectin-like receptor G1, and enhanced persistence of the transferred cells. This report is the first description of a cancer therapy with IL-17-secreting CD8(+) T cells. These findings have implications for the improvement of CD8(+) T cell-based adoptive immunotherapy.

Full Text

Duke Authors

Cited Authors

  • Hinrichs, CS; Kaiser, A; Paulos, CM; Cassard, L; Sanchez-Perez, L; Heemskerk, B; Wrzesinski, C; Borman, ZA; Muranski, P; Restifo, NP

Published Date

  • July 16, 2009

Published In

Volume / Issue

  • 114 / 3

Start / End Page

  • 596 - 599

PubMed ID

  • 19471017

Pubmed Central ID

  • 19471017

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

Digital Object Identifier (DOI)

  • 10.1182/blood-2009-02-203935


  • eng

Conference Location

  • United States